Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02319759 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 149
- Enrollment target
NCT02319759 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 149 participants.
The verdict
NCT02319759, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 149 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in participants with Active Psoriatic Arthritis (PsA).
Interventions
- DRUG Placebo
- DRUG Ustekinumab
- DRUG Guselkumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2015-03-27 |
| Est. Completion | 2017-01-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02319759
The ClinicalTrials.gov registry entry for NCT02319759 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02319759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02319759 about?
NCT02319759 is a clinical study titled "Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)". The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in participants with Active Psoriatic Arthritis (PsA).
What is the current status of trial NCT02319759?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 149 participants. The study started on 2015-03-27. Estimated completion is 2017-01-17.
What interventions are being tested in trial NCT02319759?
The interventions under investigation include: Placebo (DRUG), Ustekinumab (DRUG), Guselkumab (DRUG).
Who is sponsoring clinical trial NCT02319759?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.